AZD2423
Drugoral solution, single dose
NCT Number: NCT00970775
This is a Phase I, single centre, randomised, double-blind, placebo-controlled, parallel group study to assess the safety, tolerability and pharmacokinetics of AZD2423 following single ascending dose administration to healthy Japanese subjects.
Looking for future studies?
Notify Me20 year–55 year
All sexes
Interventional
Phase 1
Research Site, Croydon, United Kingdom
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
oral solution, single dose
oral solution,single dose
Time frame: From screening period to follow-up visit, 40 days (Maximum).
Time frame: Blood and urine sampling from pre-dose until follow-up visit, 10 days (approximately)
Time frame: Blood sampling after dosing, 3 days
AstraZeneca
Industry
A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral AZD2423 After Single Ascending Doses in Healthy Japanese Male and Non-Fertile Female Volunteers
Acronym: JSAD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07502417
Healthy Volunteer
Grayslake, Illinois, United States
View Trial DetailsNCT01934660
Cardiovascular Disease, Cardiovascular Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT06717269
Healthy Volunteer
Lincoln, Nebraska, United States
View Trial DetailsNCT00001367
Healthy Volunteer, Nervous System Disease
Bethesda, Maryland, United States
View Trial Details